Korea’s Dong-A Wins Court Battle Over Rebate-Related Price Cuts
This article was originally published in PharmAsia News
Executive Summary
The domestic pharma, in which GSK holds a minority stake, won a key battle with the government while its Korean peer Chong Kun Dang lost a similar case and saw 16 drugs take a price cut.